Biological medicinal products: reference and biosimilar products - selected issues
Biological therapies are being used in many chronic conditions. Development of biosimilar medicines gives chances for wider access to biological treatment. The aim of the review was to present legal regulations of the marketing authorisation of biological medicines in the context of biosimilars medi...
Saved in:
Main Author: | Bartosz Kobuszewski (Author) |
---|---|
Format: | Book |
Published: |
Kazimierz Wielki University,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®
by: Jakob C. Stüber, et al.
Published: (2024) -
Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products
by: Sarfaraz K. Niazi
Published: (2024) -
Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
by: Greg Cantin, et al.
Published: (2023) -
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012)